Background: Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
INTRODUCTION
Effective antiretroviral therapy (ART) has transformed the care of patients with HIV, however, cure remains elusive. Identification of individuals who achieve control of HIV infection in the absence of ART, with inquiries made into their immunologic, genetic, and virologic characteristics, may prove valuable in the quest for an HIV functional cure.
Posttreatment controllers (PTCs) are HIV-infected individuals who after discontinuing ART remain virologically suppressed with stable CD4 + T-lymphocyte counts. 1 The presence of PTCs has been examined in both prospective treatment-interruption (TI) and retrospective cohort studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Reported rates of posttreatment control are variable and have ranged from the absence of the phenotype [2] [3] [4] [5] [6] to rates ranging from 4% to 14%. [7] [8] [9] [10] [11] [12] [13] [14] This variation is partially explained by differences in baseline characteristics of the populations and the definitions of posttreatment control in these studies.
Most identified PTCs started ART during early or acute HIV infection. 1, [7] [8] [9] [10] [11] The Short Pulse Antiretroviral Therapy at Acute Seroconversion (SPARTAC) trial examined PTC in the context of early treated individuals. 8 In this large study (n = 165), 14% of individuals who were treated with .12 weeks of ART before treatment interruption maintained virologic suppression (VS) for 52 weeks and 5% remained suppressed at 104 weeks. 8 In another analysis of SPARTAC data, Martin, et al 9 compared rates of transient viral control in untreated individuals to those who had undergone treatment interruption, finding no statistically significant difference between the 2 groups. Interestingly, the PTCs tended to have higher pre-ART baseline HIV RNA levels compared with those who controlled spontaneously suggesting that PTCs may be exhibiting a unique phenomenon. 9 Retrospective cohort studies have reported incidence rates of PTCs ranging from 0% to 15% among individuals started on ART in early HIV. 6, 10, 11 PTCs have also been reported among individuals who started ART during chronic infection. [12] [13] [14] [15] In a TI study of individuals initiating ART during chronic HIV infection (CHI) rates of posttreatment control of 7.4% at 12 months and 4.2% at 36 months were reported. 13 Conversely, a TI study comparing initiation of ART during early infection versus CHI found an 8.3% rate of posttreatment control at 48 weeks among those who started ART during early infection and no posttreatment control among those who started ART during CHI. 7 Even in a highly preselected group of individuals (based on low cell-associated DNA) who initiated therapy in chronic infection and underwent a TI, the rates of PTC were 10%. 14 In a retrospective cohort study of individuals started on ART during CHI, 1.6% of individuals were reported to be PTCs. 15 Previous studies into the incidence and characteristics of PTCs have been limited by small study size and limited follow-up time among TI studies. Limitations among retrospective cohort studies include an often poor characterization of seroconversion date and, as with TI studies, a focus on individuals who started on ART during early or acute HIV infection. Given the typically long duration of follow-up and relatively accurate characterization of seroconversion date among HIV-infected individuals in the U.S. Military HIV Natural History Study (NHS) cohort, it is well designed to characterize the incidence and demographic and immunogenetic features of PTCs. 16, 17 We examined this cohort for the presence and features of PTCs.
METHODS

Study Population
NHS visits are conducted about every 6 months at 1 of 6 military treatment facilities. As service members are HIV seronegative on entry into the military and undergo mandatory HIV testing every 1-5 years the cohort is enriched in dated seroconverters, making it ideal to study this phenomenon.
During their structured interviews and through the abstraction of electronic medical records, research personnel collect clinical information [to include ART history, reasons for ART switch, CD4 counts, and viral load (VL)]. HIV-1 viral RNA determinations on EDTA plasma specimens received from Army and Navy sites were performed in a College of American Pathology accredited laboratory at Walter Reed Army Institute of Research using all generations of the Roche HIV-1 VL tests from 1997 to the present. This substudy included participants followed in the NHS between January 1, 1986 and September 16, 2016.
Definitions and Data Analysis
We retrospectively identified HIV-1-infected individuals who met the following criteria: (1) treated with ART for a period of $2 years, (2) achieved VS to ,400 copies/mL between 6 months and 2 years after ART initiation, (3) discontinued ART for $30 days and, (4) had 1 or more VL determination $30 days after ART discontinuation. Elite controllers and long-term nonprogressors, identified as HIV controllers (HICs), had been previously identified in our cohort and were excluded. 18 To avoid viral heterogeneity, we also excluded patients with known non-clade B virus infection. As the assay characteristics have varied with time, VS was defined as a VL ,400 copies/mL, and to avoid including subjects who had temporarily discontinued ART during a regimen switch, we required subjects to be off ART at-least for 30 days.
For this study, PTCs were defined as individuals who had sustained VS to ,400 copies/mL for $6 months after discontinuation of ART. We further defined those with VS for $6 months but ,2 years off of ART as "transient controllers" (TCs), and those with VS for $2 years off of ART as durable controllers (DCs). Descriptive statistics were used to describe the population, and are presented as numbers (percentages) for categorical variables and medians (interquartile ranges) for continuous variables.
RESULTS
Of the 6070 participants enrolled in the NHS, 4882 received ART at some point during their follow-up. Those infected with non-clade B virus (n = 73) and HICs (n = 21) were excluded. Figure 1 , provides details of the subjects included in this study. In brief, 1903 subjects who lacked documentation of at a VL after initiating ART and 322 with at-least 1 blip (.400 copies/mL) after starting ART were excluded. After initiating ART, 2563 subjects had documented VS (ie, to a VL ,400 copies/mL). Of those who achieved virologic suppression, 976 discontinued ART for 30 or more days. Of these, 881 lacked assessments of VL 30 or more days after discontinuation of ART (most of these likely started on a new ART regimen shortly after discontinuation of the previous regimen). In total, 95 patients met our criteria, that is, achieved VS between 6 months and 2 years after initiating ART and had 2 or more VL determinations 30 or more days after ART discontinuation.
From this group of 95, we identified 4 PTCs (4.2%). Two met our definition of TCs with suppression of viremia for 267 and 575 days off of ART and 2 met our definition of durable control with suppression of viremia for 794 days and 1058 days off of ART. Three of our PTCs were men and all were African American, their age at HIV diagnosis ranged from 21 to 38 years and time from their documented positive HIV test to ART initiation ranged from 25 to 1031 days. The number of VL determinations obtained during the period of suppression of viremia ranged from 1 to 12 (median 5, interquartile range 3.25-7.5).
Demographic and clinical characteristics of the 4 PTCs are described in Table 1 . ART history along with VLs and CD4 counts are displayed graphically in Figure 2 . Two subjects (patients #2 and #3) initiated ART relatively early after diagnosis (ie, within 25 and 56 days of being diagnosed with HIV, respectively), albeit, both individuals were in Fiebig stage V infection with fully matured Western blots at the time of their HIV diagnosis. 19 Estimating the approximate seroconversion dates in these individuals is difficult, because the last negative HIV tests in both occurred approximately 2.5 years before starting ART, and records of symptomatic primary HIV infections are lacking. Patient #3 was classified as a transient controller with viral suppression for 559 days off of ART and patient #2 as a DC with viral suppression for 794 days off of ART. The 2 other individuals (patients #1 and #4) had ART initiated during CHI at 1031 and 420 days after their documented seroconversion, respectively.
Both of the DCs (patients #2 and #4) had low baseline pre-ART VLs of 2011 and 1008 copies/mL, respectively. Among the 4 PTCs, CD4 count nadirs before ART initiation ranged from 293 to 566 cells/mL, and a majority (3 of 4) had preserved CD4 + cell counts during the period of viral suppression of off ART with counts ranging from 670 to 1155 cells/mL at the time of viral rebound. Three of the 4 PTCs were treated with a boosted protease inhibitor regimen and 1 was treated with a nonnucleoside reverse transcriptase inhibitor.
One of the 4 (patient #3) discontinued ART while being treated for Hodgkin lymphoma with ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine) and another discontinued ART to pursue alternative therapies for HIV (patient #1). It is unclear why the other 2 patients discontinued ART. Patient #2 had viral suppression for 794 days off of ART, restarted ART without ever having rebound viremia to $400 copies/mL.
Demographic and clinical characteristics of the 4 PTCs were similar to the 91 who lacked virologic control described in a Supplemental Digital Content Table, http://links.lww. com/QAI/B7.
DISCUSSION
The phenomenon of posttreatment control has rarely been described in patients who were started on ART during CHI. [12] [13] [14] [15] We describe 4 PTCs (4.2%) from a large military cohort who initiated ART during chronic infection. Our rate (4.2%) was near the range reported in previous cohorts however in most comparator studies ART was initiated in early HIV infection. 1, [7] [8] [9] [10] [11] It is thought that early initiation of ART may limit the size of the viral reservoir and allow for a more optimal immune reconstitution resulting in a stable equilibrium between a small viral reservoir and HIV-specific immune responses leading to posttreatment control. 20 The circumstances leading to a similar phenomenon among those started on ART during CHI are unclear. Immunologic studies of previously identified PTCs who started ART during CHI have reported low levels of HIV unspliced RNA in peripheral blood mononuclear cells compared with other ART-treated patients. 21 Further study of PTCs who started ART during CHI is needed to better delineate their underlying genetic, immunologic, and virologic characteristics. Peripheral blood mononuclear cell-associated HIV RNA and HIV DNA levels for reservoir quantification, HLA genotypes, expression of exhaustion and activation markers on CD4 + and CD8 + T cells and CD8 + T-cell responses to HIV peptides for genetic and immunologic characterization are planned.
Limitations of our study include the fact that therapeutic drug monitoring was not performed to confirm that the PTCs were off ART. However, we believe that surreptitious use was unlikely as our data captures use of ART paid for the by the Department of Defense. Our inclusion criteria, requiring 2 years of treatment with ART with sustained viral suppression without any VL blips $400 copies/mL, were somewhat stringent and additional PTCs may have been identified if they were relaxed. While we used strict criteria to eliminate HICs, cases may have been misclassified as PTCs when in-fact they were HICs. For example, 2 of our 4 PTCs (subjects 2 and 3) initiated ART when a set point may not have been established (ie, approximately 3 and 8 weeks after their western blot had matured). This seems unlikely given that recent studies characterizing acute HIV infection indicate that the setpoint VL occurs within 4-6 weeks of infection. 22 A majority of patients identified with HIV are identified in chronic infection. For any functional cure strategy to be successful, it is imperative that it should be applicable to those who started ART during chronic infection. Hence, examining other cohorts and pooling data to examine the determinants of PTC in chronic HIV-infected patients is essential. With the identification of individuals started on ART during chronic HIV-1 infection who went on to exhibit varying degrees of posttreatment control, our cohort study is a significant contribution to the posttreatment control literature.
